

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/51241243>

# Log-Scale Dose Response of Inhibitors on a Chip

ARTICLE *in* ANALYTICAL CHEMISTRY · JUNE 2011

Impact Factor: 5.64 · DOI: 10.1021/ac201177g · Source: PubMed

---

CITATIONS

6

---

READS

38

6 AUTHORS, INCLUDING:



Sachin Jambovane

Pacific Northwest National Laboratory

18 PUBLICATIONS 106 CITATIONS

SEE PROFILE

Published in final edited form as:

*Anal Chem.* 2011 August 15; 83(16): 6148–6153. doi:10.1021/ac201177g.

## Log-scale Dose Response of Inhibitors on a Chip

Jae Young Yun<sup>1,†</sup>, Sachin Jambovane<sup>1,†</sup>, Se-Kwon Kim<sup>2</sup>, Sung-Hak Cho<sup>3</sup>, Evert C Duin<sup>4</sup>, and Jong Wook Hong<sup>1,\*</sup>

<sup>1</sup>Materials Research and Education Center, Department of Mechanical Engineering, Auburn University, Auburn, AL 36849

<sup>2</sup>Marine Bioprocess Research Center, Pukyong National University, Busan, 608-737, Korea

<sup>3</sup>Nanomachining Laboratories, Korea Institute of Machinery and Materials, Daejeon, Korea

<sup>4</sup>Department of Chemistry and Biochemistry, Auburn University

### Abstract

We demonstrate the accommodation of log-scale concentration gradients of inhibitors on a single microfluidic chip with a semi-direct dilution capability of reagents for the determination of the half-inhibitory concentration or IC<sub>50</sub>. The chip provides a unique tool for hosting a wide-range of concentration gradient for studies that require an equal distribution of measuring points on a logarithmic scale. Using Matrix metalloproteinase IX and three of its inhibitors, marimastat, batimastat and CP471474, we evaluated the IC<sub>50</sub> of each inhibitor with a single experiment. The present work could be applied to the systematic study of biochemical binding and inhibition processes particularly in the field of mechanistic enzymology and the pharmaceutical industry.

### Keywords

Microfluidics; Logistic dose response; IC<sub>50</sub>; Log-scale concentration gradient; Inner filter effect; MMP-9; Marimastat; Batimastat; CP471474; Drug discovery

### Introduction

In the process of drug discovery, quantitative characterization of inhibitory potencies of all the potential drug candidates is necessary to figure out the best candidate<sup>1</sup>. For comparing potential drug candidates an outcome of curvefitting of a sigmoidal curve to the dose response data or the value of half maximal inhibitory concentration, IC<sub>50</sub> is used<sup>2-4</sup>. Inhibitors are small molecular weight molecules that impede the substrate molecules from reaching or binding to the enzyme active sites<sup>5</sup> and half of today's drugs are inhibitors<sup>1</sup>. In dose response analysis the use of a log-scale concentration range is important because the dose response is represented by a Maltusian-type differential equation whose solution is logarithmic type<sup>6</sup>. Recently, the importance of a log scale for drug response analysis, based on thermodynamical basis, has been reiterated<sup>7</sup>. The drug response is directly proportional to the log of the drug concentration expressed as  $\mu = RT \ln[a]$ <sup>8</sup>, where  $\mu$  is chemical potential or response of the drug and  $a$  is activity or concentration of the drug. Hence, care has to be taken to select drug concentrations that are equally spaced using a logarithmic scale instead of a linear scale.

\*Corresponding Author Footnote: 275 Wilmore Laboratories, Auburn University, Auburn AL 36849, Telephone # (334) 844-7385, Fax # (334) 844-3400 jwhong@eng.auburn.edu.

<sup>†</sup>These authors contributed equally to this work

Supporting information is available free via the Internet at <http://pubs.acs.org>

Conventionally, in the determination of  $IC_{50}$ , serial dilutions, with test tubes, vials and micro-plates, are routinely used for the preparation of a concentration gradient<sup>9</sup>. However, it is well known that the serial dilution method introduces ample errors through pipetting that directly affect the precision of each dilution ratio. Considering the required multiple steps of dilution for the realization of wide concentration ranges to obtain dose response data, the error in each step of serial dilution could lead to compounding of errors after several steps of serial dilution. This could affect the evaluation of  $IC_{50}$  values of drug candidates and their realistic comparisons. Therefore, for the evaluation of  $IC_{50}$ , direct dilution of drugs has been recommended<sup>10</sup>. During the last two decades, several studies on enzymatic reactions based on microfluidic formats have been reported<sup>11-16</sup>. The first study of enzyme inhibition on a glass chip with electrokinetic control was demonstrated by Hadd et al<sup>16</sup>. The enzyme, substrate and inhibitor were mixed at a four-way interaction of microchannels and only one reaction condition was examined without concentration gradient. A centrifugal microfluidic system with forty-eight parallel microchannel structures was shown by Duffy et al<sup>13</sup>. Because internal metering is not possible with centrifugal system in general, extra steps of off-chip concentration gradient were required to generate different reaction conditions. Few recent integrated microfluidic platforms<sup>17,18</sup> have shown the capability of conducting multi-step and parallel reactions with limited and narrow ranges of concentration gradients. Droplet-based microfluidic systems<sup>19-21</sup> have been applied to enzymatic reactions<sup>12,18,22</sup> and shown the possibility of parallel experiments with flexible concentration gradients<sup>18</sup>.

However, wide ranges of concentration gradients to test dose responses are still remained challenging. Recently, several commercial platforms<sup>10,23-26</sup> have been reported for dose response reactions using micro-titer plates and a special ejector, a piezo dispenser<sup>23,24</sup> or an acoustic droplet ejector<sup>25,26</sup>. Since the micro-titer plate is operated in an open environment, the evaporation of reagents and subsequent volumetric errors are of significant concerns at nano- or pico-liter scales<sup>27</sup>. In addition, at a given time, an ejector or a dispenser can be addressed only to a single micro well for dispensing a reagent. Therefore, the simultaneous operations of delivery, metering, gradient formation, mixing and the detection are extremely challenging for all the micro wells.

Here, we present a new approach for dose response analysis of enzyme inhibitors by using an integrated microfluidic system that has the capability of realizing a log-scale concentration gradient on a chip through semi-direct dilution of samples. To demonstrate the function of the present system, by conducting a series of dose response reactions in log-scale concentration gradients with nanoliters of drug or inhibitor samples, we measured dose response curves and determined  $IC_{50}$  values of three inhibitors, marimastat, batimastat and CP471474 for matrix metalloproteinases-9 (MMP-9) and MMP substrate III.

## Materials and methods

### Materials

The substrate QXL<sup>TM</sup>520-Pro-Leu-Gly-Cys-(Me)-His-Ala-D-Arg-Lys-(5-carboxy-fluorescein)-NH<sub>2</sub> (AnaSpec Inc), internally quenched peptide matrix of matrix metalloproteinases-9 (MMP-9) was used for the enzyme reaction. This substrate releases fluorescent signals through dissociation of the quencher (QXL<sup>TM</sup>520) and carboxyfluorescein (FAM), fluorophore, via proteolytic cleavage by enzymatic reaction. MMP-9 is known to directly or indirectly influences human diseases, such as infiltration and metastasis of cancer cell, arthritis, etc., hence, MMP-9 is one of the major targets for development of anticancer drugs<sup>28,29</sup>. For establishing a standard curve, we used reference dye, FAM-Pro-Leu-OH. The excitation and emission wavelengths for FAM are 480 nm and 520 nm, respectively. According to the enzyme reaction types, 50nM, 10 nM, and 5 nM of MMP-9 were separately dissolved into the reaction buffer (TCNBT; 50 mM Tris, 10 mM

CaCl<sub>2</sub>, 150 mM NaCl, 0.05% Brij-35, 0.05 % Tween-20 and 0.1% BSA at pH 7.5). For the substrate of MMP, a stock solution was prepared as 100  $\mu$ M in TCNBT buffer. Inhibitors of MMP-9, marimastat and batimastat (Tocris bioscience), were dissolved into DMSO in 10 mM of stock solution. Prepared reagents were stored at -20°C until dilution with TCNBT buffer for experiment.

### Device operation

As shown in Figure 1a and Supporting Figure S1, three (3) gradient formers (GF) with 14 parallel processes on a single chip. Each GF is composed of four (4) microfluidic processors, respectively. Two extra processors are added for a positive control and a negative control on the present chip. A step-by-step operation of the device is depicted in the Figure 1b. The step-by-step operation includes loading and metering of the reagents (substrate, buffer, inhibitor, and an enzyme), mixing of the metered reagents, and the scanning of the reactions. We introduced reagent 1 (substrate, FAM or inhibitor) and 2 (dilution buffer) into their respective inlet channels by applying the pressure from nitrogen gas. The inlet channels were connected to the metering channel for generating the concentration gradients. The third reagent, in this case enzyme, was filled into the enzyme part of the mixer through the reagent 3 inlet channel. The metered reagents 1 and 2 are introduced into the mixer. Now, we have all the three reagents, dilution buffer, substrate and the enzyme solution, in the mixer together maintaining complete contact of the enzyme and the diluted substrates by keeping the mechanical valves closed firmly. In this step, the two reagents were separated from the third reagent in the microreactors by two separation valves to avoid undesirable initiation of the enzyme reactions. We closed all the separation valves around the microreactor, and then opened the two separation valves between the enzyme solution (right side) and the diluted substrate (left side). The three reagents were mixed in the microreactor with sequential operation of the microvalves for peristalsis.

### Image acquisition and data processing

We used a modified biochip scanner (arrayWoRx®, Applied Precision, WA) to acquire the images of the on-chip dose response reaction. We conducted multiple scans of the part of the chip during the progress of the enzyme reactions. All the acquired images were 16-bit grayscale, the resolution was 7,800 pixels per inch (PPI), and the pixel size was 3.25  $\mu$ m. To reduce scanning time and ensure enough chip areas for data acquisition, we scanned a partial region of the fourteen microreactors (30.5 mm  $\times$  1.5 mm) as shown in Figure 2 bottom. Image acquisition software (arrayWoRx 2.5 Software Suit, Applied Precision, WA) generated the integrated scan image. The total scanning time of the integrated image (30.5 mm  $\times$  1.5 mm) was approximately 45 sec. Time series analyzer module of ImageJ software (<http://rsb.info.nih.gov/ij/>) was used to analyze and digitize all the fluorescence images. We measured the changes in the fluorescent intensity over multiple scanning processes for evaluating the photobleaching rate of FAM on the chip and corrected the digitized data. The loss of fluorescent intensities was compensated by using a similar method used for the photobleaching effect on a multiple scanned confocal image<sup>30</sup>.

### Statistical analysis

To determine the kinetic parameters,  $K_M$  and  $k_{cat}$ , the initial velocities of the individual reactions were curve-fitted with the Michaelis-Menten equation<sup>5</sup> using the enzyme kinetics module of Sigmaplot software (Systat software Inc.). For IC<sub>50</sub> values with standard error, and 95% confidence interval, we curve-fitted the four parameter nonlinear-logistic-regression model available to the inhibition data. The four parameter model is of the form<sup>2</sup> as shown below.

$$\%I = \%I_{\min} + \frac{\%I_{\max} - \%I_{\min}}{1 + 10^{(\text{Log}(IC_{50}) - [I]) \cdot h}}$$

Where,  $IC_{50}$  refers to median point of the concentration-response plot;  $[I]$  represents the concentration of inhibitor;  $h$  is the Hill coefficient or Hill slope, which means the steepness of dose-response plot;  $\%I$  designates percentage inhibiting potency, including minimum and maximum.

## Results and discussion

### Logarithmic gradient formation

In the present device, each GF has two separate inlets for inhibitor (reagent 1) and buffer (reagent 2). The three identical GFs allow conducting three repetitive experiments with fixed concentration range if we feed an inhibitor and reagent with the same concentrations. For example, if we introduce  $10\times$  inhibitor (reagent 1) and  $1\times$  working buffer (reagent 2), we can create final inhibitor concentrations of  $1\times$ ,  $2.5\times$ ,  $5\times$  and  $7.5\times$ . We can also derive a wider concentration range from the device by feeding different concentrations of inhibitor (reagent 1) in the three GFs, and by keeping the same concentration of working buffer. If we feed  $10\times$  inhibitor to the first GF1,  $100\times$  to the GF2, then  $1000\times$  to the GF3, the effective concentrations in each GF will respectively be  $1$ ,  $2.5$ ,  $5$ ,  $7.5\times$ , for GF1;  $10$ ,  $25$ ,  $50$ ,  $75\times$ , for GF2;  $100$ ,  $250$ ,  $500$ ,  $750\times$ , for GF3. Here the negative and positive control processors generate  $0$  and  $1000\times$  concentrations. Therefore, by introducing the three concentrations of inhibitor and buffer, meaningful log-scale concentrations for dose response are generated such as  $0$ ,  $1$ ,  $2.5$ ,  $5$ ,  $7.5$ ,  $10$ ,  $25$ ,  $50$ ,  $75$ ,  $100$ ,  $250$ ,  $500$ ,  $750$  and  $1000\times$  by the present device in semi-direct dilution. However, the concentration range could easily be increased by changing the input concentration of inhibitor while keeping buffer the same. In our experiments, as described in Table 1, we have created a concentration range from  $1\times$  to  $4000\times$  by using  $10\times$ ,  $200\times$  and  $4000\times$  of inhibitors for the three GFs. Note that the individual microfluidic processors has nano-liters scale volume. Hence large amount of samples could be saved during dose response analysis in comparison to the large amount of reagent volumes used in conventional methods<sup>10,24,31-33</sup>.

To confirm the generation of a logarithmic gradient using present microfluidic chip, we generated the concentration gradient of carboxyfluorescein (FAM) in the ratio of  $1:1,000$ . To generate this concentration gradient, we introduced FAM with three concentrations,  $0.05\ \mu\text{M}$ ,  $0.5\ \mu\text{M}$ , and  $5\ \mu\text{M}$ , into the reagent input ports of GF1, GF2, and GF3, respectively. The reaction buffer with a fixed concentration was also introduced to dilution buffer input ports of GF1, GF2 and GF3 (Figure 1 and Figure S1). Therefore, a concentration gradient range of  $0.0025\ \mu\text{M}$  to  $2.5\ \mu\text{M}$  was generated inside the fourteen (14) microfluidic processors. Figure 2a shows the standard curve for FAM established from 3 independent experiments conducted with log-scale gradients on a chip. In the standard curve, we observed a linear relationship, with a slope of  $1,631\ \text{AU}/\mu\text{M}$ , between concentration of FAM and the corresponding fluorescence intensity.

### Determination of kinetic parameters of enzyme reactions

The half maximal inhibitory concentration,  $IC_{50}$  can be influenced by analysis conditions, such as pH, ionic strength, substrate concentration, etc<sup>1</sup>. Among these factors the most dominant factor influencing  $IC_{50}$  value is the  $[S]/K_M$  ratio<sup>3</sup>. For the determination of  $IC_{50}$  value from a logistic-dose response curve the selection of substrate concentration equal to the value of  $K_M$  is recommended<sup>1</sup>. Therefore, we first determined the  $K_M$  value for matrix

metalloproteinase-9 (MMP-9) before measurement of the inhibiting potency of the inhibitors.

For the determination of reliable values of  $IC_{50}$  and  $K_M$ , selecting the concentration of enzyme that shows linear reaction progress is critical. To decide the enzyme concentration only part of the microfluidic chip was used. We introduced enzyme solutions of 2 nM and 20 nM to GF1 and GF2 to form an enzyme concentration gradient in the range of 0.1 nM ~ 10 nM (1:100) (Figure S2b). (We did not use the group GF3 because concentration of enzyme over 10 nM was not required.) When 50  $\mu$ M of MMP substrate III was used, it was observed that even with a measuring time of 120 minutes, the kinetic reaction did not reach the plateau for enzyme concentrations as high as 10 nM (Supplementary Figure S3a). Therefore, 10 nM of enzyme concentration was chosen to determine reaction velocities for further kinetic analysis.

To determine the kinetic parameters,  $K_M$  and  $k_{cat}$ , of MMP-9, we introduced 100  $\mu$ M substrate for GF1 and 10  $\mu$ M for GF2, respectively, along with the dilution buffer and 20 nM MMP-9 enzyme (Figure S2c). We did not use the GF3 for generating concentration gradient. As a result, 1  $\mu$ M ~ 100  $\mu$ M (1:100) of substrate concentration gradient was formed on the chip in the metering channels. After mixing the metered substrate and enzyme into the reactor mixer, the substrate concentration gradient becomes 0.5  $\mu$ M ~ 50  $\mu$ M in 9 processors (GF1, GF2 and positive control). Figure S3b shows the results of 9 independent reactions. From this plot it is observed that the rate of reaction increased with the increase of substrate concentration. The reaction rates were linear upto 10 minutes (see Figure S3b box). Therefore, the initial reaction velocity was calculated from these linear parts of the progress curves. A Michaelis-Menten plot was prepared from the initial velocity data of three repetitive experiments (Figure 3). Applying nonlinear curve-fitting to the plot, we determined  $K_M$  and  $k_{cat}$  from the on-chip experiments and the respective values were  $53.4 \pm 5.2$   $\mu$ M and  $55.8 \pm 4.1$  /min. For comparison, we conducted three off-chip experiments and the values of  $K_M$  and  $k_{cat}$  are  $41.2 \pm 4.7$   $\mu$ M and  $84.9 \pm 0.9$ /min. The deviation between on-chip and off-chip  $K_M$  values was 25.8 % whereas  $k_{cat}$  was 41.3 %. This discrepancy could be attributed to the characteristics of fluorescence detection that is relevant especially at higher substrate concentration with large optical pathlength<sup>5,34-38</sup>. Unlike absorbance based measurement the fluorescence detection experiences significant loss of fluorescence intensity at higher substrate concentrations, known as the inner filter effect (IFE)<sup>5,39</sup>. The correction factors are used to compensate for the loss of fluorescence intensity. However, the correction factors exponentially increase with the increase of substrate concentrations<sup>35,38,40</sup>. On the other hand, in our on chip experiments, we observed negligible saturation of fluorescence intensity under the same substrate concentration range (Figure 3). We assume that these differences are due to different length of optical path for on-chip, ~ 10  $\mu$ m, and off-chip, ~ 5 mm, experiments. In addition to the fact that an enzyme is an biological sample with variable properties<sup>41</sup>.

## Assessment of inhibition potencies

To show the ability of our device to generate a logarithmic concentration gradient and the functionality of our device to conduct logistic dose response studies, we determined the  $IC_{50}$  values of three inhibitors, marimastat, batimastat and CP417474, of the MMP-9 enzyme from their corresponding logistic dose response plots. Inhibitor concentration ranges of 0.063 nM ~ 250 nM (1:4000) for marimastat and batimastat and 0.25 nM ~ 1,000 nM for CP417474 were created on the chip in the 14 reactors. Note that, all the 14 reactors were used considering the requirement of a wider concentration range of inhibitors (Figure 1, Figure S1 and Figure S2), 22.15  $\mu$ M of substrate and 5 nM of enzyme was used, respectively. Figure 4 shows dose response plots for the 3 inhibitors, marimastat, batimastat



and CP417474. From these plots, the  $IC_{50}$  values for marimastat, batimastat and CP417474 are  $3.2 \pm 0.2$  nM,  $4.1 \pm 0.2$  nM and  $11.9 \pm 1.0$  nM, respectively. The respective  $IC_{50}$  values from our off-chip experiment are  $3.1 \pm 0.1$  nM (marimastat),  $3.5 \pm 0.3$  nM (batimastat) and  $14.9 \pm 0.9$  nM (CP417474). From the literature, the reported  $IC_{50}$  values for marimastat and batimastat are 3 nM<sup>42,43</sup> and 3-4 nM<sup>44,45</sup>, respectively. Through the comparison of the results from on-chip experiment and off-chip experiment, we observed the deviation of 3.2 %, 17 % and 20 % in the  $IC_{50}$  values of marimastat, batimastat, and CP417474 inhibitors, respectively. These deviations in the values of  $IC_{50}$  are acceptable, considering enzyme as a biological sample with variable properties<sup>41</sup>. Therefore, the present microfluidic chip can provide reliable determination of  $IC_{50}$  values of inhibitors with the automation of sample preparation, gradient generation, mixing, incubation and optical detection.

The present device can be used for the concentration-response analysis of reagents where a logarithmic scale concentration gradient is required. Our device could be used for various applications where log-scale gradient with flexibility of concentration range is required. The present system for example could be used for the evaluation of  $EC_{50}$ ,  $LD_{50}$  and  $LC_{50}$  by applying to microbial cells or animal cells or for conducting cell cytotoxicity assays. These dose-response or cytotoxicity experiments could be conducted by feeding the cells to the constant volume part of the mixer and forming the gradient of inhibitors or reagent, for which the toxicity limit is to be determined, in a group of reactors.

## Conclusions

In conclusion, we demonstrated a new approach of implementing log-scale concentration gradient with an integrated microfluidic chip that has semi-direct dilution capability of reagents in addition to metering and mixing of reagents with 14 parallel microfluidic processors. We showed that the concentration range from 1:0 to 1:4000 of two reagents is accommodated on the present system. We successfully determined  $IC_{50}$  values of three inhibitors of marimastat, batimastat and CP417474 for MMP-9 enzyme from the corresponding logistic dose response plots of each inhibitor with a single on chip experiment. We also confirmed that with our nanoliter-scale fluidic system inner filter effect that is common with high substrate concentrations with conventional cuvettes is avoided. We believe that the new device would be a useful tool for pharmaceutical sciences especially for the evaluation of  $IC_{50}$  of various compounds through systematic handling of reagents in nanoliter scale.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

This research was partially supported by a grant from Marine Bioprocess Research Center of the Marine Bio 21 Project funded by the Ministry of Land, Transport and Maritime, Republic of Korea. We also acknowledge partial support from the National Institutes of Health (NIH R01 008392). We thank Jing Dai and Kim Cramer for their help during the preparation of the manuscript.


## References

1. Copeland, R. Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. John Wiley and Sons; 2005.
2. Motulsky, H.; Christopoulos, A. Fitting models to biological data using linear and nonlinear regression: a practical guide to curve fitting. Oxford University Press; USA: 2004.
3. Copeland RA. Analytical Biochemistry. 2003; 320:1. [PubMed: 12895464]

4. Cortes A, Cascante M, Cardenas M, Cornish-Bowden A. *Biochemical Journal*. 2001; 357:263. [PubMed: 11415458]
5. Copeland, R. *Enzymes: a practical introduction to structure, mechanism, and data analysis*. Wiley-Vch; 2000.
6. Rozman K, Kerecsen L, Viluksela M, OÖsterle D, Deml E, Viluksela M, Stahl B, Greim H, Doull J. *Drug metabolism reviews*. 1996; 28:29. [PubMed: 8744588]
7. Waddell WJ. *Toxicology and Applied Pharmacology*. 2008; 228:156. [PubMed: 18191974]
8. Atkins, P.; De Paula, J. *Elements of physical chemistry*. WH Freeman & Co; 2009.
9. Seefeldt S, Jensen J, Fuerst E. *Weed Technology*. 1995; 9:218.
10. Hüser, J. *High-throughput screening in drug discovery*. Vch Verlagsgesellschaft MbH; 2006.
11. Kerby M, Chien RL. *Electrophoresis*. 2001; 22:3916. [PubMed: 11700721]
12. Song H, Ismagilov RF. *J Am Chem Soc*. 2003; 125:14613. [PubMed: 14624612]
13. Duffy DC, Gillis HL, Lin J, Sheppard NF, Kellogg GJ. *Anal Chem*. 1999; 71:4669.
14. Miller EM, Wheeler AR. *Anal Chem*. 2008; 80:1614. [PubMed: 18220413]
15. Kang JH, Park JK. *Sens Actuators B*. 2005; 107:980.
16. Hadd AG, Raymond DE, Halliwell JW, Jacobson SC, Ramsey JM. *Analytical Chemistry*. 1997; 69:3407. [PubMed: 9286159]
17. Jambovane S, Duin EC, Kim SK, Hong JW. *Analytical Chemistry*. 2009; 81:3239. [PubMed: 19338287]
18. Jambovane S, Kim DJ, Duin EC, Kim SK, Hong JW. *Analytical Chemistry*. 2011; 83:3358. [PubMed: 21456571]
19. Thorsen T, Roberts RW, Arnold FH, Quake SR. *Physical Review Letters*. 2001; 86:4163. [PubMed: 11328121]
20. Lee W, Jambovane S, Kim D, Hong J. *Microfluidics and Nanofluidics*. 2009; 7:431.
21. Abate, AR.; Hung, T.; Mary, P.; Agresti, JJ.; Weitz, DA. *Proceedings of the National Academy of Sciences*; 2010; p. 19163
22. Bui MPN, Li CA, Han KN, Choo J, Lee EK, Seong GH. *Analytical Chemistry*. 2011; 83:1603. [PubMed: 21280615]
23. Niles W, Coassin P. *Assay and Drug Development Technologies*. 2005; 3:189. [PubMed: 15871693]
24. Quintero C, Rosenstein C, Hughes B, Middleton R, Kariv I. *Journal of Biomolecular Screening*. 2007; 12:891. [PubMed: 17517899]
25. Massé, F.; Guiral, S.; Kargman, S.; Brideau, C. 2005
26. Ellson R, Mutz M, Browning B, Lee L, Miller MF, Papen R. *Journal of the Association for Laboratory Automation*. 2003; 8:29.
27. Dunn DA, Feygin I. *Drug Discovery Today*. 2000; 5:S84.
28. Hooper, N. *Zinc metalloproteases in health and disease*. CRC; 1996.
29. Baguley, B.; Kerr, D. *Anticancer drug development*. Academic Pr; 2002.
30. McGrath JL, Tardy Y, Dewey CF, Meister JJ, Hartwig JH. *Biophys J*. 1998; 75:2070. [PubMed: 9746549]
31. Olechno J, Shieh J, Ellson R. *Journal of the Association for Laboratory Automation*. 2006; 11:240.
32. Harris D, Olechno J, Datwani S, Ellson R. *Journal of Biomolecular Screening*. 2010; 15:86. [PubMed: 20008122]
33. Lee K, Kim C, Kim Y, Jung K, Ahn B, Kang J, Oh K. *Biomedical microdevices*. 2010; 12:297. [PubMed: 20077018]
34. Lakowicz, J. *Principles of fluorescence spectroscopy*. Springer; 2006.
35. MacDonald BC, Lvin SJ, Patterson H. *Analytica Chimica Acta*. 1997; 338:155.
36. Liu Y, Kati W, Chen C, Tripathi R, Molla A, Kohlbrenner W. *Analytical Biochemistry*. 1999; 267:331. [PubMed: 10036138]
37. Fanget B, Devos O, Draye M. *Analytical Chemistry*. 2003; 75:2790. [PubMed: 12948151]
38. Kubista M, Sjoback R, Eriksson S, Albinsson B. *Analyst*. 1994; 119:417.




39. Lakowicz J, Masters B. *Journal of Biomedical Optics*. 2008; 13:029901.
40. Gu Q, Kenny J. *Analytical Chemistry*. 2008; 81:420. [PubMed: 19063673]
41. Cornish-Bowden, A. *Analysis of enzyme kinetic data*. Oxford; United Kingdom: 1995.
42. Brown P. *id*. 2000; 9:2167.
43. Rao B. *Current pharmaceutical design*. 2005; 11:295. [PubMed: 15723627]
44. Asahi M, Asahi K, Jung J, del Zoppo G, Fini M, Lo E. *Journal of Cerebral Blood Flow & Metabolism*. 2000; 20:1681. [PubMed: 11129784]
45. Rasmussen H, McCann P. *Pharmacology and Therapeutics*. 1997; 75:69. [PubMed: 9364582]




**Figure 1.**


Design and operation of the microfluidic device. (a) 3D view of the chip. The chip is composed of three (3) different gradient formers (GF) with four microfluidic processors for each GF. Two extra processors are added for a positive and a negative controls resulting in 14 parallel reactions at the same time. (b) Step by step operation of single GF. Although a GF is composed of four reactors positive and negative controls are explained together.



**Figure 2.** Log-log scale standard curve for FAM with the scanned image of FAM concentration gradients.



**Figure 3.** Determination of enzyme kinetic parameters,  $K_M$  and  $k_{cat}$ . Comparison of on-chip and off-chip results indicates no need of inner filter effect correction factor for on-chip data. The off-chip velocities, after applying correction factor, shows marked improvement in the velocities at each substrate concentration. The error bar is obtained from three individual experiments. The exponential nature of corrector factor increases the magnitude of error bar, especially at higher substrate concentrations in corrected off-chip velocity data.



**Figure 4.**

The logistics dose response plots for three inhibitors, marimastat, batimastat and CP471474, of MMP-9 enzyme. The dose-response plot for each inhibitor was obtained from three on-chip experiments. The  $IC_{50}$  values for each inhibitor were calculated by curvefitting the four parameter model to the inhibitory activity data.

Table 1

Compositions and concentrations of reagents introduced into an integrated microfluidic chip to accommodate a log-scale gradient.

GFs	Reagents introduced into metering channels			Constant reagent	Final concentrations of metered reagents	Relative concentration ranges <sup>b</sup>
	Reagent 1	Reagent 2	Reagent 3			
[FAM] gradient [nM]	GF1 5000				2,500.00	~ 250.00
	GF2 500		buffer		187.50	~ 25.00
	GF3 50				18.75	~ 2.50
[E] gradient [nM]	GF1 20.0				10.00	~ 1.00
	GF2 2.0	buffer	50 $\mu$ M substrate in buffer		0.75	~ 0.1
	GF3 buffer				0	0
[S] gradient [ $\mu$ M]	GF1 100.0				50.00	~ 5.00
	GF2 10.0		5 nM MMP-9 in buffer		3.75	~ 0.50
	GF3 buffer				0	0
[Marimastat] [nM]	GF1 500.00 <sup>a</sup>				250	~ 25
	GF2 25.00 <sup>a</sup>				9.375	~ 1.250
	GF3 1.25 <sup>a</sup>				0.469	~ 0.063
[CP 417474] [nM]	GF1 2,000.00 <sup>a</sup>				1,000	~ 100
	GF2 100.00 <sup>a</sup>	44.3 $\mu$ M substrate in buffer	10 nM MMP-9 in buffer		37.5	~ 5
	GF3 5.00 <sup>a</sup>				1.875	~ 0.25
[Batimastat] [nM]	GF1 500.00 <sup>a</sup>				250	~ 25
	GF2 25.00 <sup>a</sup>				9.375	~ 1.250
	GF3 1.25 <sup>a</sup>				0.469	~ 0.063

<sup>a</sup>Inhibitor solutions included 44.3  $\mu$ M substrate

Ranges and concentrations were calculated with 13 microfluidic processors excluding a negative control